An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose to evaluate the effectiveness of duloxetine in treating subjects
with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD). The
investigators hypothesize that duloxetine as a single therapeutic agent will effectively
target pain and other core symptoms of IBS as well as GAD in this patient population with
both conditions.